Terms: = Lung cancer AND IL6ST, CDw130, 3572, ENSG00000134352, P40189, IL6R-beta, GP130-RAPS, GP130, CD130 AND Prognosis
5 results:
1. Farnesoid X receptor promotes non-small cell lung cancer metastasis by activating Jak2/STAT3 signaling via transactivation of IL-6ST and IL-6 genes.
Jin X; Shang B; Wang J; Sun J; Li J; Liang B; Wang X; Su L; You W; Jiang S
Cell Death Dis; 2024 Feb; 15(2):148. PubMed ID: 38360812
[TBL] [Abstract] [Full Text] [Related]
2. Interleukin-6 and insulin-like growth factor-1 synergistically promote the progression of NSCLC.
Tang H; Bai Y; Pan G; Wang X; Wei Y; Yang Z; Zhao J
Autoimmunity; 2018 Dec; 51(8):399-407. PubMed ID: 30604632
[TBL] [Abstract] [Full Text] [Related]
3. Interaction between epidermal growth factor receptor and interleukin-6 receptor in NSCLC progression.
Yuquan B; Hexiao T; Laiyi W; Gaofeng P; Xuefeng Z; Ming X; Yanhong W; Li Z; Jinping Z
J Cell Biochem; 2019 Jan; 120(1):872-881. PubMed ID: 30132982
[TBL] [Abstract] [Full Text] [Related]
4. Plumbagin suppresses the human large cell lung cancer cell lines by inhibiting IL-6/STAT3 signaling in vitro.
Yu T; Xu YY; Zhang YY; Li KY; Shao Y; Liu G
Int Immunopharmacol; 2018 Feb; 55():290-296. PubMed ID: 29294439
[TBL] [Abstract] [Full Text] [Related]
5. Low incidence of il6st (gp130) mutations in exon 6 in lung cancer of a Chinese cohort.
Sun L; Sui L; Cong X; Ma K; Ma X; Huang Y; Fan C; Fu X; Ma K
Cancer Genet; 2014; 207(7-8):291-8. PubMed ID: 25242236
[TBL] [Abstract] [Full Text] [Related]
